Premium
Interleukin‐3 administration enhances human monocyte function in vivo
Author(s) -
Khwaja Asim,
Addison Ian E.,
Johnson Beryl,
Yong Kwee,
Linch David C.
Publication year - 1994
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1994.tb05067.x
Subject(s) - monocyte , in vivo , eosinophil , phagocytosis , immunology , medicine , andrology , endocrinology , biology , asthma , microbiology and biotechnology
Summary. In addition to its haemopoietic effects, interleukin‐3 (IL‐3) enhances leucocyte function in vitro . In this study we examined the effects on haematological variables and monocyte function of a single IL‐3 infusion in five haematologically normal individuals. There was a rapid fall in circulating monocyte (to 24 ± 6% of pre‐infusion value) and eosinophil numbers (to 3 ± 2%) with a nadir at 30 min and gradual return to baseline over 6h. No significant changes in monocyte expression of the adhesion molecules CD11b or L‐selectin or of monocyte respiratory burst activity were detected. There was a significant increase in monocyte phagocytosis and killing of Canadida after IL‐3 infusion: the percentage of monocytes which had ingested Candida increased from 39 ± 10% to 62 ± 12% and the total number of Candida killed per 100 monocytes increased from 63 ± 34 to 210 ± 59 ( P < 0.05 and P < 0.01 respectively). There was no inhibition of neutrophil migration into a ‘skin window’ site and monocyte migration was moderately enhanced (peak increase of 260 ± 47%). These results show that IL‐3 has significant effects on monocyte function in vivo and could be of use in augmenting host defence mechanisms in immunocompromised patients.